Under construction – not a live service
Sign in
Taking people in ChinaPhase 2/3

Tests adagrasib alone and with pembrolizumab in lung cancer with a KRAS G12C change

Tests adagrasib, alone or with pembrolizumab, in adults with lung cancer.

Plain-language title generated from the registry record
Registry title: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Key facts

Where
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Liuzhou, Luzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Ürümqi, Wuhan, Xi'an, Xiamen, Xinxiang, Xuzhou, Yinchuan, and Zhengzhou, ChinaSee the 155 sites
Phase
Phase 2/3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation and who have not yet had treatment for it.

Age
18 years or older
Sex
Men and women can join.
Disease stage
Non-small cell lung cancer that cannot be removed by surgery or has spread. Phase 3 asks for squamous or nonsquamous NSCLC with PD-L1 TPS of 50% or higher and measurable disease. Phase 2 accepts any PD-L1 TPS.
Earlier treatment
People cannot have had earlier systemic treatment for advanced or metastatic NSCLC, including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C (for example AMG 510).
Biomarker or test result
KRAS G12C mutation. Phase 3 also needs PD-L1 TPS of 50% or higher.

Main reasons for not taking part

  • Earlier systemic treatment for advanced or metastatic NSCLC
  • Phase 2: active brain metastases
  • Phase 3: untreated brain lesions larger than 2.0 cm (0.8 in), or any brainstem lesions
  • Phase 3: steroids above 10 mg of prednisone a day for brain lesion symptoms, or seizures more than 1 a week
  • Phase 3: radiation to the lung above 30 Gy within 6 months before the first dose

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Which best describes your lung cancer?
  • Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?

Source: NCT04613596, who can take part

Where in China

  • Beijing Cancer HospitalBeijing, ChinaContact: Jun Zhao, Site 007-038-Ph3Taking people
  • Beijing Cancer Hospital/Thoracic Oncology(2nd) DepartmentBeijing, ChinaContact: Jian Fang, Site 007-040-Ph3Taking people
  • Cancer Hospital Chinese Academy of Medical Sciences/Medical Oncology DepartmentBeijing, ChinaContact: Yan Wang, Site 007-050-Ph3Taking people
  • Beijing, Beijing MunicipalityHospital not named in the registryNo longer taking part
  • Local Institution - 007-027-Ph2Beijing, ChinaNo longer taking part
  • Local Institution - 007-038Beijing, ChinaNo longer taking part
  • Local Institution - 007-038-Ph2Beijing, ChinaNo longer taking part
  • Local Institution - 007-040Beijing, ChinaNo longer taking part
  • Local Institution - 007-040-Ph2Beijing, ChinaNo longer taking part
  • Local Institution - 007-050Beijing, ChinaNo longer taking part
  • Local Institution - 007-707Beijing, ChinaNo longer taking part
  • Local Institution - 007-707-Ph2Beijing, ChinaNo longer taking part
  • Local Institution - 1025-Ph2Beijing, ChinaNo longer taking part
  • The First Affiliated Hospital of Bengbu Medical College/Department of Respiratory and Critical Care MedicineBengbu, ChinaContact: Chengling Zhao, Site 007-051-Ph3Taking people
  • Local Institution - 007-051Bengbu, ChinaNo longer taking part
  • The First Bethune Hospital Of Jilin University/Oncology DepartmentChangchun, ChinaContact: Jiuwei Cui, Site 007-717-Ph3Taking people
  • Changchun, JilinHospital not named in the registryNo longer taking part
  • Local Institution - 007-717-Ph2Changchun, ChinaNo longer taking part
  • Local Institution - 1006-Ph2Changchun, ChinaNo longer taking part
  • Hunan Cancer hospital Thoracic Medicine Department IIChangsha, ChinaContact: Lin Wu, Site 007-701-Ph3Taking people
  • Local Institution - 007-701-Ph2Changsha, ChinaNo longer taking part
  • Sichuan Cancer HospitalChengdu, ChinaContact: Wenxiu Yao, Site 007-710-Ph3Taking people
  • West China Hospital of Sichuan UniversityChengdu, ChinaContact: Panwen Tian, Site 007-720-Ph3Taking people
  • Local Institution - 007-710Chengdu, ChinaNo longer taking part
  • Local Institution - 007-710-Ph2Chengdu, ChinaNo longer taking part
  • Local Institution - 007-720-Ph2Chengdu, ChinaNo longer taking part
  • Chongqing University Three Gorges Hospital/Respiratory Ward of Tumor CenterChongqing, ChinaContact: Biyong Ren, Site 007-053-Ph3Taking people
  • Chongqing, Chongqing MunicipalityHospital not named in the registryNo longer taking part
  • Local Institution - 007-053Chongqing, ChinaNo longer taking part
  • Local Institution - 007-718-Ph3Chongqing, ChinaNo longer taking part
  • Local Institution - 1029-Ph2Chongqing, ChinaNo longer taking part
  • Fujian Cancer HospitalFuzhou, ChinaContact: Wu Zhuang, Site 007-039-Ph3Taking people
  • Fuzhou, FujianHospital not named in the registryNo longer taking part
  • Local Institution - 007-039Fuzhou, ChinaNo longer taking part
  • Local Institution - 007-039-Ph2Fuzhou, ChinaNo longer taking part
  • Local Institution - 1046-Ph2Fuzhou, ChinaNo longer taking part
  • Nanfang Hospital, Southern Medical University/Respiratory Medicine DepartmentGuangzhou, ChinaContact: Laiyu Liu, Site 007-705-Ph3Taking people
  • The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaContact: Chengzhi Zhou, Site 007-712-Ph3Taking people
  • Guangzhou, GuangdongHospital not named in the registryNo longer taking part
  • Local Institution - 007-705Guangzhou, ChinaNo longer taking part
  • Local Institution - 007-705-Ph2Guangzhou, ChinaNo longer taking part
  • Local Institution - 007-712Guangzhou, ChinaNo longer taking part
  • Local Institution - 007-712-Ph2Guangzhou, ChinaNo longer taking part
  • Local Institution - 1022-Ph2Guangzhou, ChinaNo longer taking part
  • The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaContact: Jianying Zhou, Site 007-716-Ph3Taking people
  • Zhejiang Cancer HospitalHangzhou, ChinaContact: Zhengbo Song, Site 007-037-Ph3Taking people
  • Local Institution - 007-036Hangzhou, ChinaNo longer taking part
  • Local Institution - 007-036-Ph2Hangzhou, ChinaNo longer taking part
  • Local Institution - 007-037-Ph2Hangzhou, ChinaNo longer taking part
  • Local Institution - 007-716Hangzhou, ChinaNo longer taking part
  • Local Institution - 007-716-Ph2Hangzhou, ChinaNo longer taking part
  • Cancer Hospital affiliated to Harbin Medical University/Ward 3 of Respiratory Medicine DepartmentHarbin, ChinaContact: Yan Yu, Site 007-028-Ph3Taking people
  • Local Institution - 007-028Harbin, ChinaNo longer taking part
  • Local Institution - 007-028-Ph2Harbin, ChinaNo longer taking part
  • Anhui Provincial HospitalHefei, ChinaContact: Junqiang Zhang, Site 007-747-Ph3Taking people
  • Local Institution - 007-026Hefei, ChinaNo longer taking part
  • Local Institution - 007-026-Ph2Hefei, ChinaNo longer taking part
  • Local Institution - 007-739Hefei, ChinaNo longer taking part
  • Local Institution - 007-739-Ph2Hefei, ChinaNo longer taking part
  • Local Institution - 007-747Hefei, ChinaNo longer taking part
  • Shandong Cancer HospitalJinan, ChinaContact: Haiyong Wang, Site 007-708-Ph3Taking people
  • Local Institution - 007-708-Ph2Jinan, ChinaNo longer taking part
  • Kunming, YunnanHospital not named in the registryNo longer taking part
  • Local Institution - 007-385Kunming, ChinaNo longer taking part
  • Local Institution - 007-385-Ph3Kunming, ChinaNo longer taking part
  • Local Institution - 007-745Kunming, ChinaNo longer taking part
  • Local Institution - 007-745-Ph2Kunming, ChinaNo longer taking part
  • Local Institution - 1032-Ph2Kunming, ChinaNo longer taking part
  • Linyi Cancer Hospital/Oncology DepartmentLinyi, ChinaContact: Jianhua Shi, Site 007-737-Ph3Taking people
  • Local Institution - 007-703Linyi, ChinaNo longer taking part
  • Local Institution - 007-703-Ph2Linyi, ChinaNo longer taking part
  • Local Institution - 007-737-Ph2Linyi, ChinaNo longer taking part
  • Local Institution - 007-704Liuzhou, ChinaNo longer taking part
  • Local Institution - 007-704-Ph2Liuzhou, ChinaNo longer taking part
  • Local Institution - 007-711Luzhou, ChinaNo longer taking part
  • Local Institution - 007-711-Ph2Luzhou, ChinaNo longer taking part
  • The First Affiliated Hospital of NanChang UniversityNanchang, ChinaContact: Longhua Sun, Site 007-713-Ph3Taking people
  • Nanchang, JiangxiHospital not named in the registryNo longer taking part
  • Local Institution - 007-713-Ph2Nanchang, ChinaNo longer taking part
  • Local Institution - 1040-Ph2Nanchang, ChinaNo longer taking part
  • Nanjing First Hospital/Department of Respiratory and Critical Care MedicineNanjing, ChinaContact: Surong Fang, Site 007-706-Ph3Taking people
  • Nanjing First Hospital/Respiratory DepartmentNanjing, ChinaContact: Wei Gu, Site 007-706-Ph2Taking people
  • Nanjing, JiangsuHospital not named in the registryNo longer taking part
  • Nanjing, JiangsuHospital not named in the registryNo longer taking part
  • Nanjing, JiangsuHospital not named in the registryNo longer taking part
  • Local Institution - 1018-Ph2Nanjing, ChinaNo longer taking part
  • Local Institution - 1020-Ph2Nanjing, ChinaNo longer taking part
  • Local Institution - 1021-Ph2Nanjing, ChinaNo longer taking part
  • Guangxi Medical University Cancer Hospital/Department of Respiratory OncologyNanning, ChinaContact: Qitao Yu, Site 007-384-Ph3Taking people
  • Nanning, GuangxiHospital not named in the registryNo longer taking part
  • Local Institution - 007-384Nanning, ChinaNo longer taking part
  • Local Institution - 007-744-Ph2Nanning, ChinaNo longer taking part
  • Local Institution - 1038-Ph2Nanning, ChinaNo longer taking part
  • Nantong, JiangsuHospital not named in the registryNo longer taking part
  • Local Institution - 1004-Ph2Nantong, ChinaNo longer taking part
  • QingdaoHospital not named in the registryNo longer taking part
  • Local Institution - 1043-Ph2Qingdao, ChinaNo longer taking part
  • Fudan University Shanghai Cancer Center/Thoracic Oncology DepartmentShanghai, ChinaContact: Jialei Wang, Site 007-035-Ph3Taking people
  • Shanghai Chest Hospital-Oncology departmentShanghai, ChinaContact: Shun Lu, Site 007-709-Ph3Taking people
  • Local Institution - 007-024Shanghai, ChinaNo longer taking part
  • Local Institution - 007-024-Ph2Shanghai, ChinaNo longer taking part
  • Local Institution - 007-024-Ph3Shanghai, ChinaNo longer taking part
  • Local Institution - 007-035Shanghai, ChinaNo longer taking part
  • Local Institution - 007-035-Ph2Shanghai, ChinaNo longer taking part
  • Local Institution - 007-709Shanghai, ChinaNo longer taking part
  • Local Institution - 007-709-Ph2Shanghai, ChinaNo longer taking part
  • Shengjing Hospital Of China Medical UniversityShenyang, ChinaContact: Xiaoye Zhang, Site 007-749-Ph3Taking people
  • Shenyang, LiaoningHospital not named in the registryNo longer taking part
  • Local Institution - 007-702Shenyang, ChinaNo longer taking part
  • Local Institution - 007-702-Ph2Shenyang, ChinaNo longer taking part
  • Local Institution - 007-741Shenyang, ChinaNo longer taking part
  • Local Institution - 007-741-Ph2Shenyang, ChinaNo longer taking part
  • Local Institution - 007-749Shenyang, ChinaNo longer taking part
  • Local Institution - 1008-Ph2Shenyang, ChinaNo longer taking part
  • Shenzhen People's Hospital/Department of Respiratory and Critical Care MedicineShenzhen, ChinaContact: Di Wu, Site 007-052-Ph3Taking people
  • Local Institution - 007-052Shenzhen, ChinaNo longer taking part
  • The Fourth Hospital of Hebei Medical UniversityShijiazhuang, ChinaContact: Cuimin Ding, Site 007-742-Ph3Taking people
  • Local Institution - 007-742Shijiazhuang, ChinaNo longer taking part
  • Shanxi Provincial Cancer Hospital/Respiratory MedicineTaiyuan, ChinaContact: Jianchun Duan, Site 007-748-Ph3Taking people
  • Local Institution - 007-740Taiyuan, ChinaNo longer taking part
  • Local Institution - 007-740-Ph2Taiyuan, ChinaNo longer taking part
  • Local Institution - 007-748Taiyuan, ChinaNo longer taking part
  • Taizhou Hospital of Zhejiang ProvinceTaizhou, ChinaContact: Dongqing Lv, Site 007-744-Ph3Taking people
  • Taizhou, ZhejiangHospital not named in the registryNo longer taking part
  • Local Institution - 1050-Ph2Taizhou, ChinaNo longer taking part
  • Ürümqi, XinjiangHospital not named in the registryNo longer taking part
  • Local Institution - 007-743Ürümqi, ChinaNo longer taking part
  • Local Institution - 007-743-Ph3Ürümqi, ChinaNo longer taking part
  • Local Institution - 1036-Ph2Ürümqi, ChinaNo longer taking part
  • Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology/Cancer Center DepartmentWuhan, ChinaContact: Xiaorong Dong, Site 007-719-Ph3Taking people
  • Local Institution - 007-700Wuhan, ChinaNo longer taking part
  • Local Institution - 007-700-Ph2Wuhan, ChinaNo longer taking part
  • Local Institution - 007-719-Ph2Wuhan, ChinaNo longer taking part
  • The First Affiliated Hospital of Xi'an Jiaotong University/Medical Oncology DepartmentXi'an, ChinaContact: Yu Yao, Site 007-721-Ph3Taking people
  • Local Institution - 007-718-Ph2Xi'an, ChinaNo longer taking part
  • Local Institution - 007-721Xi'an, ChinaNo longer taking part
  • Local Institution - 007-721-Ph2Xi'an, ChinaNo longer taking part
  • The First Affiliated Hospital of Xiamen University/Medical Oncology DepartmentXiamen, ChinaContact: Feng Ye, Site 007-732-Ph3Taking people
  • Local Institution - 007-714Xiamen, ChinaNo longer taking part
  • Local Institution - 007-714-Ph2Xiamen, ChinaNo longer taking part
  • Local Institution - 007-732Xiamen, ChinaNo longer taking part
  • Local Institution - 007-732-Ph2Xiamen, ChinaNo longer taking part
  • Local Institution - 1012-Ph2Xinxiang, ChinaNo longer taking part
  • Xuzhou, JiangsuHospital not named in the registryNo longer taking part
  • Local Institution - 1017-Ph2Xuzhou, ChinaNo longer taking part
  • Local Institution - 007-746Yinchuan, ChinaNo longer taking part
  • Local Institution - 007-746-Ph3Yinchuan, ChinaNo longer taking part
  • Henan Cancer Hospital/Second Ward of Respiratory Medicine DepartmentZhengzhou, ChinaContact: Yanqiu Zhao, Site 007-021-Ph3Taking people
  • Zhengzhou, HenanHospital not named in the registryNo longer taking part
  • Local Institution - 007-021-Ph2Zhengzhou, ChinaNo longer taking part
  • Local Institution - 007-715Zhengzhou, ChinaNo longer taking part
  • Local Institution - 007-715-Ph2Zhengzhou, ChinaNo longer taking part
  • Local Institution - 007-730-Ph2Zhengzhou, ChinaNo longer taking part
  • Local Institution - 007-730-Ph3Zhengzhou, ChinaNo longer taking part
  • Local Institution - 1010-Ph2Zhengzhou, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Mirati Therapeutics Inc.
Trial code
NCT04613596EU 2023-508922-83-00
Record updated
30 October 2026
Original description
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.Read full original descriptionShow less

A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.

The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS >=50% and who are candidates for first line treatment.

Inclusion: Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation and any PD-L1 TPS; Phase 3: Histologically confirmed diagnosis of unresectable or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS>=50%; Phase 3: Presence of measurable disease per RECIST1.1; Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of the following:; No evidence of brain metastases; Untreated brain metastases not needing immediate local therapy; Previously treated brain metastases not needing immediate local therapy.

Exclusion: Phase 2 and Phase 3: Prior systemic treatment for locally advanced or metastatic NSCLC including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation (e.g., AMG 510); Phase 3: Patients with known central nervous system (CNS) lesions must not have any of the following:; Any untreated brain lesions > 2.0 cm in size; Any brainstem lesions; Ongoing use of systemic corticosteroids for control of symptoms of brain lesions at a total daily dose of > 10 mg of prednisone (or equivalent) prior to randomization; Have poorly controlled (> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain lesions notwithstanding CNS-directed therapy; Phase 3: Radiation to the lung > 30 Gy within 6 months prior to the first dose of study treatment; Phase 2: Active brain metastases.

ClinicalTrials.gov NCT04613596 · EU CTIS 2023-508922-83-00